Off-label uses of rituximab in dermatology

被引：27
|
作者：
Carr, David R. [1 ]
Heffernan, Michael P. [1 ]
机构：
[1] Wright State Univ, Sch Med, Div Dermatol, Dayton, OH 45408 USA
来源：
DERMATOLOGIC THERAPY | 2007年 / 20卷 / 04期
关键词：
biologics; rituximab;
D O I：
10.1111/j.1529-8019.2007.00141.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many case reports have indicated rituximab's efficacy in a number of inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side effect profile, as well as a review of the current literature on off-label uses of the CD20(+) B-cell antagonist rituximab.
引用
收藏
页码：277 / 287
页数：11
相关论文
共 50 条
  • [21] Off-label uses of trazodone: a review
    Bossini, Letizia
    Casolaro, Ilaria
    Koukouna, Despoina
    Cecchini, Federica
    Fagiolini, Andrea
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (12) : 1707 - 1717
  • [22] Off-label uses of drugs in children
    Blumer, JL
    [J]. PEDIATRICS, 1999, 104 (03) : 598 - 602
  • [23] Off-label Uses of Topical Pimecrolimus
    Ladda, Matthew
    Sandhu, Vijay
    Ighani, Arvin
    Yeung, Jensen
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2019, 23 (04) : 442 - 448
  • [24] Off-label Studies on the Use of Ruxolitinib in Dermatology
    Tegtmeyer, Kyle
    Ravi, Mohan
    Zhao, Jeffrey
    Maloney, Nolan J.
    Lio, Peter A.
    [J]. DERMATITIS, 2021, 32 (03) : 164 - 172
  • [25] Off-Label studies on anakinra in dermatology: a review
    Tegtmeyer, Kyle
    Atassi, Giancarlo
    Zhao, Jeffrey
    Maloney, Nolan J.
    Lio, Peter A.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 73 - 86
  • [26] Off-label studies on tofacitinib in dermatology: a review
    Tegtmeyer, Kyle
    Zhao, Jeffrey
    Maloney, Nolan J.
    Atassi, Giancarlo
    Beestrum, Molly
    Lio, Peter A.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (04) : 399 - 409
  • [27] Off-label studies on apremilast in dermatology: a review
    Maloney, Nolan J.
    Zhao, Jeffrey
    Tegtmeyer, Kyle
    Lee, Ernest Y.
    Cheng, Kyle
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (02) : 131 - 140
  • [28] Off-label studies on ruxolitinib in dermatology: a review
    Wu, Jessica
    Smogorzewski, Jan
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 606 - 612
  • [29] Rituximab: A warning concerning off-label use
    Lynn, Shari J.
    [J]. AMERICAN JOURNAL OF NURSING, 2007, 107 (05) : 29 - 29
  • [30] Ivabradine: A Review of Labeled and Off-Label Uses
    Oliphant, Carrie S.
    Owens, Ryan E.
    Bolorunduro, Oluwaseyi B.
    Jha, Sunil K.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (05) : 337 - 347
12345